Cassava Sciences Inc vs W W Grainger Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while W W Grainger Inc trades at $1,305.49 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 1284.2× Cassava Sciences Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | GWW | |
|---|---|---|
Market Cap | $47.75M | $61.32B |
Sector | Health | Technology |
52-Week High | $4.64 | $1.40K |
52-Week Low | $0.87 | $918.18 |
Enterprise Value | -$34.93M | $63.53B |
Dividend Yield | — | 0.77% |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.
Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →